San Diego, Nov. 23, 2011 (Shareholders Foundation) -- An investigation on behalf of investors in shares of The Cooper Companies, Inc. (NYSE: COO) over potential securities laws violations by the Cooper Companies and /or certain officers and directors was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of The Cooper Companies (NYSE COO) concerning whether the company, certain of its officers and directors, or others have possibly violated federal securities laws. Specifically, the investigation concerns whether certain statements regarding The Cooper Companies business, its prospects and its operations were potentially materially false and misleading at the time they were made.

Pleasanton, California-based Cooper Companies, Inc, through its wholly-owned subsidiary CooperVision, develops, manufactures, and globally markets contact lenses.

The Cooper Companies, Inc. reported that its annual Revenue rose from $945.24million for 2007 to $1.15billion in 2010 and its Net Income increased from a Net Loss of $11.19million in 07 to a Net Income of $112.80million in 2010. Its second quarter Revenue rose from $295.63million last year to $351.40million this year, but its second quarter Net Income fell from $.39.73million to $38.14million.

Shares of the Cooper Companies, Inc. (Public, NYSE:COO) rose from as low as $11.52 in November 08 to over $80 in July.

Then on Aug. 19, 2011, the Cooper Companies, Inc. announced that its subsidiary CooperVision has initiated a recall on limited lots of Avaira Toric contact lenses. Cooper Companies, Inc said that the recall is limited solely to specific lots of Avaira Toric, and no other CooperVision product is involved in this recall.

NYSE:COO shares traded on August 19, 2011 as low as $66.22 per share but the increased in September to $83 per share.

On October 11, 2011 it was reported that the U.S. Food and Drug Administration (FDA) seemed ready to take action in the form of a public warning. A spokeswoman for the FDA reportedly said that Absent prompt and adequate communication by CooperVision, the FDA may independently share its concerns about Avaira Toric contact lenses. On October 13, 2011 the Cooper Companies announced that it continued to recall its Avaira Toric Contact Lenses. Cooper Companies said it is cooperating with the United States Food and Drug Administration (FDA).

Then on November 15, 2011, the Cooper Companies, Inc. (NYSE:COO) announced that its subsidiary CooperVision has expanded its recall on limited lots of Avaira Toric contact lenses to include limited lots of Avaira Sphere contact lenses. Cooper Companies said CooperVision is expanding the recall because it identified certain lots of Avaira Sphere lenses that did not meet its updated quality requirements due to the level of a silicone oil residue.

Shares of the Cooper Companies (NYSE COO) fell from $83 per share in September 2011 to as low as $52.97 per share on November 15, 2011.